Clinical Trials Logo

Leiomyoma clinical trials

View clinical trials related to Leiomyoma.

Filter by:

NCT ID: NCT00156208 Completed - Uterine Fibroids Clinical Trials

Safety of Treatment of Uterine Fibroids With Asoprisnil

Start date: April 2004
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the long-term safety of asoprisnil in women with symptomatic uterine fibroids who completed the 6 month Study C02-037.

NCT ID: NCT00156195 Completed - Menorrhagia Clinical Trials

Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids

Start date: September 2003
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the long-term safety of asoprisnil in women with abnormal uterine bleeding associated with uterine fibroids.

NCT ID: NCT00156182 Completed - Leiomyoma Clinical Trials

A Long-Term Safety Study of Asoprisnil in the Treatment of Uterine Fibroids.

Start date: April 2001
Phase: Phase 2
Study type: Interventional

This study was designed to determine the long-term safety of asoprisnil 10 mg in women with one or more uterine fibroids after an initial 12 weeks in study M99-144.

NCT ID: NCT00156156 Completed - Uterine Fibroids Clinical Trials

Study of Asoprisnil in the Treatment of Uterine Fibroids.

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the long-term safety of asoprisnil in women with abnormal uterine bleeding associated with uterine fibroids.

NCT ID: NCT00152269 Completed - Menorrhagia Clinical Trials

Treatment of Uterine Fibroids With Asoprisnil(J867)

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the safety and effectiveness of asoprisnil in symptomatic women with abnormal uterine bleeding associated with uterine fibroids.

NCT ID: NCT00152256 Completed - Uterine Fibroids Clinical Trials

A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids

Start date: September 2003
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the safety and efficacy effects of two doses of asoprisnil (10 mg and 25 mg) compared with placebo when administered daily for 6 months to premenopausal subjects with symptomatic uterine leiomyomata.

NCT ID: NCT00150644 Completed - Uterine Fibroids Clinical Trials

A Study to Evaluate the Effects of Asoprisnil(J867) in Women With Uterine Fibroids Who Are Scheduled for a Hysterectomy

Start date: July 2003
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the effects of 10 mg and 25 mg doses of asoprisnil, compared to placebo, taken daily for 12 weeks, on uterine blood flow and the morphology of the endometrium and uterine fibroids.

NCT ID: NCT00133705 Completed - Leiomyoma Clinical Trials

Trial of Mifepristone for Fibroids

Start date: July 2003
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to determine if low-dose mifepristone benefits women with symptomatic fibroids.

NCT ID: NCT00131365 Completed - Leiomyoma Clinical Trials

Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids

Start date: January 2006
Phase: N/A
Study type: Interventional

The goal of this study is to develop additional long term data to evaluate the safety and effectiveness of this treatment. Indications for use for this system is: 'The ExAblate is intended to ablate uterine fibroid tissue in pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure. Patients must have a uterine size of less than 24 weeks and not seeking treatment for reasons of improving fertility.'

NCT ID: NCT00100191 Completed - Menorrhagia Clinical Trials

Emmy Trial: Uterine Artery Embolization (UAE) Versus Hysterectomy for Uterine Fibroids

Start date: February 2002
Phase: Phase 3
Study type: Interventional

The Emmy trial is set up to evaluate the safety and efficacy of uterine artery embolization (UAE) in comparison to hysterectomy for the treatment of symptomatic uterine fibroids. UAE was considered equivalent to hysterectomy when at least 75% of patients had normalization of heavy menstrual blood loss after treatment.